Gal-3 Protein Expression and Localization in Prostate Tumours.
Tânia LimaCatarina Macedo-SilvaDiana MontezumaJoão FragaIsa CarneiroCarmen JerónimoRui M HenriqueMargarida FardilhaRui VitorinoPublished in: Current oncology (Toronto, Ont.) (2023)
Gal-3 plays an important role in cell survival, mRNA splicing, and cell-cell and cell-matrix interactions. Depending on its cellular localization and cancer type, Gal-3 may have tumour-suppressive or tumour-promoting activities. Given the promising diagnostic role of Gal-3 in the urine of PCa patients found in our previous study, its concordant gene and protein expression levels, and its involvement in PCa-related biological processes (e.g., morphogenesis of the prostate gland epithelium), we aimed to investigate this protein immunohistochemically in tumour and normal prostate tissues. Gal-3 protein expression was evaluated in 48 tumour prostate tissues, eight normal prostate tissues and 14 adjacent-normal prostate tissues. Decreased Gal-3 staining was detected in tumour tissues compared with normal tissues. Although Gal-3 staining was decreased in tumour tissues with GS 5-8 and pT2 and pT3 stages compared with normal prostate tissue, no correlation was found between Gal-3 expression and PCa progression. In the present study, the pattern of cellular localization differed between groups, as Gal-3 was predominantly excluded from the nucleus in tumour tissues. Furthermore, Gal-3 had no significant effect on survival and relapse in these PCa patients. This work confirms Gal-3 as a promising marker for PCa diagnosis.
Keyphrases
- prostate cancer
- gene expression
- benign prostatic hyperplasia
- end stage renal disease
- single cell
- ejection fraction
- peritoneal dialysis
- cell therapy
- newly diagnosed
- poor prognosis
- young adults
- binding protein
- squamous cell carcinoma
- prognostic factors
- mesenchymal stem cells
- transcription factor
- genome wide identification
- flow cytometry
- long non coding rna